Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies

A large retrospective study from Switzerland and the United States, involving women aged 40 to 89, found no increased risk of blood clots in those using oral oestrogen compared with those using transdermal forms such as patches or gels. These findings offer reassurance that, for many women, oral oestrogen is a safe option when prescribed appropriately and monitored with good clinical oversight.

This plain-language summary is provided for educational purposes and does not replace individual medical advice.